Testing linperlisib for acquired pure red cell aplasia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a drug called linperlisib in people with acquired pure red cell aplasia (aPRCA) that has not responded to at least two prior treatments. The goal is to see if linperlisib can help your body make more red blood cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with acquired pure red cell aplasia.
- Your condition has not improved after at least two prior treatments, or it came back after treatment.
- Your hemoglobin level is 100 g/L or lower.
- If you take steroids like prednisone, you have been on a stable low dose (15 mg or less per day) for at least 2 weeks.
- If you take other immune-suppressing drugs like cyclosporine or sirolimus, you must be on a stable dose for at least 3 months and stop them when you start the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant using a milder conditioning regimen and a drug called post-transplant cyclophosphamide to treat severe aplastic anemia and other acquired bone marrow failure conditions. The goal is to help patients achieve a functioning donor bone marrow with fewer side effects.
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
This trial tests a drug called Linprixel for people with autoimmune hemolytic anemia (AIHA) that has come back or hasn't responded to at least two previous treatments. The goal is to see if it can help control the disease with manageable side effects.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This study tests a drug called luspatercept to see if it can improve anemia in people with rare inherited red blood cell disorders. It may help reduce the need for blood transfusions or raise hemoglobin levels.
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
Hear when a new Acquired Pure Red Cell Aplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.